UltraTech Cement rose 4.8% to Rs 5790.70 after the company reported 122.8% surge in consolidated net profit to Rs 1584.58 crore on 17.4% increase in net sales to Rs 12,254.12 crore in Q3 December 2019.Profit before tax surged 133.8% to Rs 2331.98 crore in Q3 December 2020 over Q3 December 2019. Current tax expense soared to Rs 408.92 crore in Q3 December 2020 as against Rs 165.3 crore in Q3 December 2019.
EBITDA jumped 57% to Rs 3362 crore in Q3 December 2020 from Rs 2147 crore recorded in Q3 December 2019. EBITDA margin improved by 700 basis points to 28% in Q3 December 2020 from Rs 21% in Q3 December 2019.
UltraTech said recovery from COVID-19 led disruption has been rapid and this has fuelled by quicker demand stabilization, supply side restoration and greater cost efficiencies.
(2)
January 25, 2021
Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care
Amsterdam, the Netherlands -
Royal Philips).
The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT together comprised approximately 600 patients in Europe and the U.S. After five years, the ILLUMENATE EU RCT showed 19.3% mortality among patients treated with the Stellarex DCB compared to 19.4% mortality for those treated with PTA. The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA (20.2%). Both studies had a high vital status follow-up compliance, with the status of over 90% of patients known.
Read more about Lupin gains on USFDA nod for hyperphosphatemia medication on Business Standard. Lupin rose 1.54% to Rs 1096.20 after the drug major received US drug regulator s approval for Sevelamer Carbonate tablets.
ISLAMABAD: The Pakistan People’s Party’s proposal to go for a no-confidence motion against Prime Minister Imran Khan rather than opting for other options to oust him has never elicited.